Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis.


Journal

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966

Informations de publication

Date de publication:
11 2022
Historique:
received: 10 11 2021
revised: 11 03 2022
accepted: 06 04 2022
pubmed: 20 4 2022
medline: 7 12 2022
entrez: 19 4 2022
Statut: ppublish

Résumé

Mucus hyperconcentration in cystic fibrosis (CF) lung disease is marked by increases in both mucin and DNA concentration. Additionally, it has been shown that half of the mucins present in bronchial alveolar lavage fluid (BALF) from preschool-aged CF patients are present in as non-swellable mucus flakes. This motivates us to examine the utility of mucus flakes, as well as mucin and DNA concentrations in BALF as markers of infection and inflammation in CF airway disease. In this study, we examined the mucin and DNA concentration, as well as mucus flake abundance, composition, and biophysical properties in BALF from three groups; healthy adult controls, and two CF cohorts, one preschool aged and the other school aged. BALFs were characterized via refractometry, PicoGreen, immunofluorescence microscopy, particle tracking microrheology, and fluorescence image tiling. Mucin and DNA BALF concentrations increased progressively from healthy young adult controls to preschool-aged people and school-aged people with CF. Notably, mucin concentrations were increased in bronchoalveolar lavage fluid (BALF) from preschool-aged patients with CF prior to decreased pulmonary function. Infrequent small mucus flakes were identified in normal subjects. A progressive increase in the abundance of mucus flakes in preschool and school-aged CF patients was observed. Compositionally, MUC5B dominated flakes from normal subjects, whereas an increase in MUC5AC was observed in people with CF, reflected in a reduced flaked MUC5B/MUC5AC mucin ratio. These findings suggest mucus composition and flake properties are useful markers of inflammatory and infection-based changes in CF airways.

Sections du résumé

BACKGROUND
Mucus hyperconcentration in cystic fibrosis (CF) lung disease is marked by increases in both mucin and DNA concentration. Additionally, it has been shown that half of the mucins present in bronchial alveolar lavage fluid (BALF) from preschool-aged CF patients are present in as non-swellable mucus flakes. This motivates us to examine the utility of mucus flakes, as well as mucin and DNA concentrations in BALF as markers of infection and inflammation in CF airway disease.
METHODS
In this study, we examined the mucin and DNA concentration, as well as mucus flake abundance, composition, and biophysical properties in BALF from three groups; healthy adult controls, and two CF cohorts, one preschool aged and the other school aged. BALFs were characterized via refractometry, PicoGreen, immunofluorescence microscopy, particle tracking microrheology, and fluorescence image tiling.
RESULTS
Mucin and DNA BALF concentrations increased progressively from healthy young adult controls to preschool-aged people and school-aged people with CF. Notably, mucin concentrations were increased in bronchoalveolar lavage fluid (BALF) from preschool-aged patients with CF prior to decreased pulmonary function. Infrequent small mucus flakes were identified in normal subjects. A progressive increase in the abundance of mucus flakes in preschool and school-aged CF patients was observed. Compositionally, MUC5B dominated flakes from normal subjects, whereas an increase in MUC5AC was observed in people with CF, reflected in a reduced flaked MUC5B/MUC5AC mucin ratio.
CONCLUSION
These findings suggest mucus composition and flake properties are useful markers of inflammatory and infection-based changes in CF airways.

Identifiants

pubmed: 35437233
pii: S1569-1993(22)00097-2
doi: 10.1016/j.jcf.2022.04.008
pii:
doi:

Substances chimiques

Mucin 5AC 0
Biomarkers 0
DNA 9007-49-2

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

959-966

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016086
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no competing or conflicting interests to disclose that are relevant to this work.

Auteurs

Matthew R Markovetz (MR)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA. Electronic address: matthew_markovetz@med.unc.edu.

Ian C Garbarine (IC)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA.

Cameron B Morrison (CB)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA.

William J Kissner (WJ)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA.

Ian Seim (I)

Department of Mathematics, University of North Carolina, Chapel Hill, USA; Department of Applied Physical Sciences, University of North Carolina, Chapel Hill, USA.

M Gregory Forest (MG)

Department of Mathematics, University of North Carolina, Chapel Hill, USA; Department of Applied Physical Sciences, University of North Carolina, Chapel Hill, USA; Department of Biomedical Engineering, University of North Carolina, Chapel Hill, USA.

Micah J Papanikolas (MJ)

Department of Applied Physical Sciences, University of North Carolina, Chapel Hill, USA.

Ronit Freeman (R)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA; Department of Applied Physical Sciences, University of North Carolina, Chapel Hill, USA.

Agathe Ceppe (A)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA.

Andrew Ghio (A)

National Health and Environmental Effects Research Laboratory, United States Environmental Protection Agency, University of North Carolina, Chapel Hill, USA.

Neil E Alexis (NE)

Center for Environmental Medicine Asthma and Lung Biology, University of North Carolina, Chapel Hill, USA.

Stephen M Stick (SM)

Telethon Kids Institute, University of Western Australia, Perth, Australia; Division of Pediatrics, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia.

Camille Ehre (C)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA.

Richard C Boucher (RC)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA.

Charles R Esther (CR)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA; Division of Pediatric Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Marianne S Muhlebach (MS)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA; Division of Pediatric Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

David B Hill (DB)

Marsico Lung Institute, University of North Carolina, Chapel Hill, USA; Department of Physics and Astrophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Electronic address: david_b_hill@med.unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH